There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xilio Therapeutics (XLO – Research Report) and Neurocrine (NBIX – Research Report) with bullish sentiments.
Xilio Therapeutics (XLO)
TD Cowen analyst Marc Frahm maintained a Buy rating on Xilio Therapeutics today. The company’s shares closed last Thursday at $1.60.
According to TipRanks.com, Frahm is a 4-star analyst with an average return of
Currently, the analyst consensus on Xilio Therapeutics is a Strong Buy with an average price target of $8.00, representing a 344.4% upside. In a report issued on November 6, Morgan Stanley also maintained a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Neurocrine (NBIX)
In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on Neurocrine, with a price target of $134.00. The company’s shares closed last Thursday at $112.15.
According to TipRanks.com, Shibutani is a 5-star analyst with an average return of
Currently, the analyst consensus on Neurocrine is a Moderate Buy with an average price target of $134.17, which is a 15.8% upside from current levels. In a report issued on October 31, TD Cowen also maintained a Buy rating on the stock with a $125.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on XLO:
- Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
- Xilio Therapeutics price target lowered to $6 from $9 at Guggenheim
- Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
- Xilio reports initial monotherapy safety and anti-tumor activity data for XTX202
- Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
